发布求助
文献互助 智能选刊 最新文献

PARP抑制后的铂化疗在HRR缺陷的转移性阉割耐药前列腺癌中的应用

IF 2.3 3区 医学 Q3 ONCOLOGY
Clinical genitourinary cancer Pub Date : 2024-08-10 DOI:10.1016/j.clgc.2024.102187
Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari
{"title":"PARP抑制后的铂化疗在HRR缺陷的转移性阉割耐药前列腺癌中的应用","authors":"Jennifer Obasi ,&nbsp;Komal Sharma ,&nbsp;Navonil De Sarkar ,&nbsp;Emmanuel S. Antonarakis ,&nbsp;Deepak Kilari","doi":"10.1016/j.clgc.2024.102187","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102187"},"PeriodicalIF":2.3000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer\",\"authors\":\"Jennifer Obasi ,&nbsp;Komal Sharma ,&nbsp;Navonil De Sarkar ,&nbsp;Emmanuel S. Antonarakis ,&nbsp;Deepak Kilari\",\"doi\":\"10.1016/j.clgc.2024.102187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>\",\"PeriodicalId\":10380,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":\"22 6\",\"pages\":\"Article 102187\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767324001587\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001587","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

-在这部分患者中，如果 PARP 抑制剂失效后未检测到逆转突变，可考虑使用卡铂进行挽救。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
分享
查看原文 本刊更多论文
Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

  • •

    PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.

  • •

    A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.

  • •

    In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.

求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
Clinical genitourinary cancer
Clinical genitourinary cancer 医学-泌尿学与肾脏学
CiteScore
5.20
自引率
6.20%
发文量
201
审稿时长
54 days
期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信